Incyte Corp. (INCY) Inks License Agreement with Novartis for Oncology Treatment
Incyte Corp. is a development company focused on oncology, inflammation and diabetes treatments. The company recently announced an agreement with Novartis regarding two of its investigational hemotology-oncology therapies. INCB18424 is an oral inhibitor in phase III development for myelofibrosis, a potentially fatal condition that includes bone marrow failure, splenic enlargement and debilitating constitutional symptoms. INCB28060 is an oral inhibitor that will soon be in phase I development as treatment for multiple cancers. The license and collaboration agreement calls for Incyte to keep the exclusive rights for the development and commercialization of INCB18424 in the United States. Novartis will be responsible…